EyeGage utilizes mobile eye scans and AI-based analysis to detect substance impairment in individuals operating high-risk equipment, such as vehicles and machinery. This technology addresses the significant issue of substance abuse in the workforce, which contributes to over $600 billion in annual costs and increases the risk of fatal accidents in industries like transportation, construction, and healthcare.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for detecting substance impairment, such as urine drug tests, are often administered after an incident, may be inaccurate, and can be time-consuming. The lack of readily available and objective screening tools increases the risk of accidents and reduces overall safety in high-risk work environments. Substance abuse in the workforce leads to significant economic losses and potential fatalities across various industries.
Solution
EyeGage offers a mobile, AI-powered solution for rapid substance impairment detection through eye scans. The technology uses a mobile device to capture images and videos of the eyes, classifying features like the pupil and iris. AI algorithms then analyze these features to identify potential drug or alcohol impairment. This allows for quick and accurate screening before operating equipment, improving safety and compliance in high-risk workplaces. The system detects various substances, including alcohol, amphetamines, benzodiazepines, opioids, and marijuana, by recognizing substance-specific changes in eye behavior.
Target Audience
The primary target audience includes employers in high-risk industries such as hospitals, construction, manufacturing, and transportation, as well as insurance companies and automotive OEMs focused on safety.
Features
- Mobile app for on-the-spot eye scans and analysis
- AI-based detection of alcohol, amphetamines, benzodiazepines, opioids, and marijuana
- Rapid results for immediate decision-making
- Objective assessment of impairment, reducing reliance on subjective observations
- Data capture and reporting for compliance tracking